All In Biotech

Drug Trial Radar · NCT06909253

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 3, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Conditions

  • Myasthenia Gravis, Generalized

Interventions

  • RavulizumabDrug

    Ravulizumab, concentrate for solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total scoreTime frame: at 6 month

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Bydgoszcz, Poland · Recruiting

  • Research Site

    Gdansk, Poland · Recruiting

  • Research Site

    Katowice, Poland · Recruiting

  • Research Site

    Krakow, Poland · Recruiting

  • Research Site

    L DZ, Poland · Recruiting

  • Research Site

    Lublin, Poland · Recruiting

  • Research Site

    Poznan, Poland · Recruiting

  • Research Site

    Szczecin, Poland · Recruiting

  • Research Site

    Szczecin, Poland · Withdrawn

  • Research Site

    Warsaw, Poland · Recruiting

  • Research Site

    Wroclaw, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.